<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="518">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05154409</url>
  </required_header>
  <id_info>
    <org_study_id>EVT_CTC_01</org_study_id>
    <nct_id>NCT05154409</nct_id>
  </id_info>
  <brief_title>Blood and Urine Sample Collection From Healthy Volunteers</brief_title>
  <official_title>Blood and Urine Sample Collection From Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evotec International GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Evotec International GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to obtain blood and urine samples from healthy volunteers to serve as&#xD;
      a healthy control group for cross-cohort comparisons.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to obtain peripheral venous blood samples and a urine sample from 100&#xD;
      healthy volunteers on one day at three different times of the day, to serve as a healthy&#xD;
      control group for cross-cohort comparisons.&#xD;
&#xD;
      With the help of the urine and blood samples obtained in this context, a cohort of a healthy&#xD;
      collective is to be established for further research purposes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 22, 2021</start_date>
  <completion_date type="Actual">May 27, 2021</completion_date>
  <primary_completion_date type="Actual">May 27, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Collection of blood samples from healthy volunteers to serve as a healthy control group.</measure>
    <time_frame>1 day</time_frame>
    <description>There are no primary endpoints planned; endpoints will be specified in the individual research projects that will utilize the blood samples as a control group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Collection of urine samples from healthy volunteers to serve as a healthy control group.</measure>
    <time_frame>1 day</time_frame>
    <description>There are no primary endpoints planned; endpoints will be specified in the individual research projects that will utilize the urine samples as a control group.</description>
  </primary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Healthy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy Volunteers who met all inclusion and none of the exlusion criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female subjects aged 40-70 years.&#xD;
&#xD;
          -  Caucasian&#xD;
&#xD;
          -  Non-smokers or ex-smokers&#xD;
&#xD;
          -  Body Mass Index (BMI): ≥18.5 and ≤32 kg/m2&#xD;
&#xD;
          -  Presence of a negative SARS-CoV-2 PCR test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Complaints that may indicate the presence of an infection, including Covid-19.&#xD;
&#xD;
          -  Pathological alcohol consumption.&#xD;
&#xD;
          -  Positive alcohol breath test at the preliminary examination.&#xD;
&#xD;
          -  Alcohol consumption within the last 24 hours before the start of sampling.&#xD;
&#xD;
          -  History of drug dependence.&#xD;
&#xD;
          -  Positive urine drug test during the preliminary examination.&#xD;
&#xD;
          -  Clinically significant acute or chronic disease. In particular, chronic inflammation,&#xD;
             rheumatological and other autoimmune diseases, diabetes and other metabolic diseases.&#xD;
&#xD;
          -  Indications in the medical history or during the medical examination that may&#xD;
             jeopardize the safety of the study participant by participating in the study.&#xD;
&#xD;
          -  History of relevant clinically significant cardiovascular disorders or clinically&#xD;
             relevant hyper- or hypotension or clinically relevant brady- or tachycardia at&#xD;
             screening as assessed by an investigator.&#xD;
&#xD;
          -  Heart rate &lt;45/min after 5 minutes in a quiet sitting position.&#xD;
&#xD;
          -  Heart rate &gt;100/min after 5 minutes in a quiet sitting position.&#xD;
&#xD;
          -  Systolic blood pressure of &gt; 170 mmHg or &lt; 90 mmHg.&#xD;
&#xD;
          -  Diastolic blood pressure of &gt; 95 mmHg and/or &lt; 60 mmHg.&#xD;
&#xD;
          -  Regular use of prescription medication within 3 months prior to inclusion in the&#xD;
             research project.&#xD;
&#xD;
          -  Use of non-prescription medications within 3 days prior to inclusion in the research&#xD;
             project.&#xD;
&#xD;
          -  Presence of clinically significant food intolerance and/or food allergy as assessed by&#xD;
             the investigator.&#xD;
&#xD;
          -  Medically relevant previous operations.&#xD;
&#xD;
          -  Condition following radio- or chemotherapy.&#xD;
&#xD;
          -  History of oncological diseases.&#xD;
&#xD;
          -  Blood and/or plasma donation within the last 30 days prior to sample collection.&#xD;
&#xD;
          -  Pregnant or nursing female.&#xD;
&#xD;
          -  Employees of study site.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanna Peradziryi</last_name>
    <role>Study Chair</role>
    <affiliation>Hanna.Peradziryi@evotec.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CTC North</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

